US 12,139,567 B2
Curable composition, cured product, and compound
Ryutaro Sugawara, Kawasaki (JP); and Takuro Asaba, Kawasaki (JP)
Assigned to TOKYO OHKA KOGYO CO., LTD., Kawasaki (JP)
Filed by TOKYO OHKA KOGYO CO., LTD., Kawasaki (JP)
Filed on Dec. 1, 2021, as Appl. No. 17/457,108.
Claims priority of application No. 2020-201362 (JP), filed on Dec. 3, 2020.
Prior Publication US 2022/0177625 A1, Jun. 9, 2022
Int. Cl. C08F 222/22 (2006.01); C07D 401/12 (2006.01); C07D 401/14 (2006.01); C07D 403/12 (2006.01); C07D 403/14 (2006.01); C07D 407/12 (2006.01); C07D 407/14 (2006.01); C07D 413/12 (2006.01); C07D 413/14 (2006.01); C07D 417/12 (2006.01); C07D 471/04 (2006.01); C07D 471/08 (2006.01); C08F 22/22 (2006.01); C08F 26/06 (2006.01); C08F 122/22 (2006.01); C08F 126/06 (2006.01); C08F 222/24 (2006.01); C08F 226/06 (2006.01); C08F 20/34 (2006.01); C08F 20/36 (2006.01); C08F 20/38 (2006.01); C08F 22/24 (2006.01); C08F 120/34 (2006.01); C08F 120/36 (2006.01); C08F 120/38 (2006.01); C08F 122/24 (2006.01); C08F 220/34 (2006.01); C08F 220/38 (2006.01)
CPC C08F 222/22 (2013.01) [C07D 401/12 (2013.01); C07D 401/14 (2013.01); C07D 403/12 (2013.01); C07D 403/14 (2013.01); C07D 407/12 (2013.01); C07D 407/14 (2013.01); C07D 413/12 (2013.01); C07D 413/14 (2013.01); C07D 417/12 (2013.01); C07D 471/04 (2013.01); C07D 471/08 (2013.01); C08F 22/22 (2013.01); C08F 26/06 (2013.01); C08F 122/22 (2013.01); C08F 126/06 (2013.01); C08F 222/24 (2013.01); C08F 226/06 (2013.01); C08F 20/34 (2013.01); C08F 20/36 (2013.01); C08F 20/38 (2013.01); C08F 22/24 (2013.01); C08F 120/34 (2013.01); C08F 120/36 (2013.01); C08F 120/38 (2013.01); C08F 122/24 (2013.01); C08F 220/34 (2013.01); C08F 220/385 (2020.02); C08F 220/387 (2020.02)] 6 Claims
 
1. A curable composition comprising a polymerizable heterocyclic compound (A) and an initiator (C),
wherein the polymerizable heterocyclic compound (A) is a compound represented by the following formula (A1):

OG Complex Work Unit Chemistry
wherein RA1 is an optionally substituted quinolinyl group, an optionally substituted isoquinolinyl group, or a 2-substituted benzothiazolyl group as RA1, the 2-substituted benzothiazolyl group having a group represented by —S—RA0 at the 2-position, wherein RA0 is a hydrogen atom, a radically polymerizable group-containing group, or a cationically polymerizable group-containing group; wherein the 2-substituted benzothiazolyl group as RA1 may have a substituent other than the group represented by —S—RA0 at a position other than the 2-position, RA2 and RA3 each are an aromatic-ring-containing group having a radically polymerizable group-containing group or an aromatic-ring-containing group having a cationically polymerizable group-containing group; and —NH— groups bonded to the triazine ring are each bonded to the aromatic ring in RA2 and RA3.